Review of preclinical and clinical studies of using cell‐based therapy for secondary lymphedema

Chen, Ching-En; Chiang, Nai‐Jung; Perng, Cherng-Kang; Ma, Hsu; Lin, Chih‐Hsun

doi:10.1002/jso.25661

Cited by 16 publications

(20 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Physiological function of the lymphatics is to return proteinaceous fluid, including proteins, lipids, and water, from the interstitium to the intravascular space. Main pathological changes of postmastectomy lymphedema are the impaired lymph fluid drainage and lymphatic vascular insufficiency 2 . Disrupted outflow of lymphatic fluid in the upper extremity causes a cascade of pathological reorganization in tissue structure.…”

Section: Pathophysiological Mechanisms Of Postmastectomy Lymphedema Dmentioning

confidence: 99%

“…Chen et al 2 . analyzed the existing data on human and animal application of stem cell treatment in current practice.…”

Section: Therapeutic Effect Of Stem Cell In Lymphedemamentioning

confidence: 99%

“…analyzed the existing data on human and animal application of stem cell treatment in current practice. The authors state that current knowledge and experimental data provide significant insight into the efficacy of stem cell therapy procedures, even with existing differences in animal modeling of lymphedema 2 . The early clinical trials provide encouraging treatment outcomes, which offers an alternative to solve tough clinical problems that has long remained unsolved.…”

Section: Therapeutic Effect Of Stem Cell In Lymphedemamentioning

confidence: 99%

“…Main pathological changes of postmastectomy lymphedema are the impaired lymph fluid drainage and lymphatic vascular insufficiency. 2 Disrupted outflow of lymphatic fluid in the upper extremity causes a cascade of pathological reorganization in tissue structure. The specific structure of the lymphatic vessels allows for the transfer of large proteins and lipids into the lymph, as well as large amounts of interstitial fluid.…”

Section: Pathophysiological Mechanisms Of Postmastectomy Lymphedema Developmentmentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review

Chen

Sinelnikov

Reshetov

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

Upper limb lymphedema is one of the most common complications after breast cancer surgery and radiotherapy. Despite various physical therapy and surgical options available, the impaired lymph fluid drainage may be progressive due to lymphatic vascular insufficiency making treatment more difficulty. Stem cell therapy provides a promising alternative in the treatment of various chronic diseases. The wide applicability of cell therapy has been reviewed throughout literature. This review provides an overview of recent progress in the therapeutic effect of adult stem cells for primary and secondary lymphedema after breast surgery in preclinical studies and clinical cases. We start with a brief introduction about the pathophysiological mechanisms of postmastectomy lymphedema. Regarding existing treatments, we systematically summarize the benefits and limitations of recent progress. Because of their multidirectional differentiation potential and growth factor secretion, stem cell therapy shows promising results in the management of light to severe lymphedema. Increasing evidences have demonstrated a noticeable reduction in postmastectomy lymphedema and increased lymph‐angiogenesis after specific stem cell therapy. Current data suggests that stem cell therapy in lymphedema treatment provides reversal of pathological reorganization associated with lymphedema progression. Finally, we propose potential strategies for overcoming the challenges in the development of multipotent progenitor cells for the treatment and prevention of lymphedema in clinical practice.

show abstract

Section: Pathophysiological Mechanisms Of Postmastectomy Lymphedema Dmentioning

confidence: 99%

“…Chen et al 2 . analyzed the existing data on human and animal application of stem cell treatment in current practice.…”

Section: Therapeutic Effect Of Stem Cell In Lymphedemamentioning

confidence: 99%

Section: Therapeutic Effect Of Stem Cell In Lymphedemamentioning

confidence: 99%

Section: Pathophysiological Mechanisms Of Postmastectomy Lymphedema Developmentmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review

Chen

Sinelnikov

Reshetov

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…The pathophysiology of lymphedema remains poorly understood due to the lack of suitable animal models[ 25 , 26 ]. Rodent tails and hindlimb models fail to accurately recapitulate latent onset in the human body, which ranges from 3 mo to 3 years[ 27 , 28 ]. However, a positive feedback loop is widely accepted during lymphedema development, involving local inflammation, the fibrosis of lymphatic vessels, and the deposition of adipose fat[ 29 , 30 ].…”

Section: Pathological Changes During Lymphedemamentioning

confidence: 99%

Adipose-derived stem cell therapy shows promising results for secondary lymphedema

Pan

2020

WJSC

View full text Add to dashboard Cite

Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system. Secondary lymphedema attributed to cancer therapy, parasite infection, and trauma remains a serious global disease. Patients with lymphedema suffer swelling, pain, and fatigue, with the dysfunction of the deformed extremities reducing the quality of life and increasing the risk of infection and lymphangiosarcoma. Adipose-derived stem cells (ADSCs) possess prominent regenerative potential to differentiate into multilineage cells, and produce various lymphangiogenic factors, making ADSC therapy a promising approach for lymphedema. The development of lymphedema consists of local inflammation, the fibrosis of lymphatic vessels, and the deposition of adipose fat. Existing animal models do not mimic the chronic inflammation environment, therefore suitable models are required in further studies. Some signal pathways and molecular mechanisms in physiological and pathological lymphagiogenesis remain unclear. In previous animal and human trials, ADSC therapy reduced edema in varying degrees. A larger number of trials with larger samples and longer follow-up periods are required to verify the efficiency and feasibility of ADSC therapy. ADSCs are of easy availability and immune exemption, making them a candidate for lymphedema treatment. Whether ADSCs enhance malignant characteristics or trigger the malignant change deserves further exploration and study before ADSC therapy can be made widely available.

show abstract

Stem Cell Therapy for Lymphedema

McLaughlin

Cheng

Brewster

2020

Stem Cell Therapy for Vascular Diseases

View full text Add to dashboard Cite

Review of preclinical and clinical studies of using cell‐based therapy for secondary lymphedema

Cited by 16 publications

References 59 publications

Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review

Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review

Adipose-derived stem cell therapy shows promising results for secondary lymphedema

Stem Cell Therapy for Lymphedema

Contact Info

Product

Resources

About